Physician profile
Michael W Winter
NPI 1003172180
$57,755.22
in general payments reported to CMS, 2019-2025
10 companies · $3,679 in 2025
The $3,679 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2021: $3,306 · 2024: $362 · 2025: $3,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,256 · Travel and Lodging: $694 · Food and Beverage: $91.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,255.50 |
| Travel and Lodging | $694.25 |
| Food and Beverage | $91.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50,000.00 | 2019 | |
| Celltrion USA INC. | $3,679.42 | 2025 | Zymfentra |
| Abbvie INC. | $3,522.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $361.95 | 2024 | |
| Celgene Corporation | $55.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.62 | 2019 | |
| Acell, INC. | $25.62 | 2019 | |
| Shire North American Group INC | $14.79 | 2019 | |
| Dynavax Technologies Corporation | $3.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.